Servier acquires Day One Biopharma

Servier agreed to acquire Day One Biopharma. Reported deal value: $2.5B. Status: Pending. Sector: medical. Target headquarters context: Brisbane, California, United States.

This page summarizes publicly available information about the transaction as of 2026-03-09. Figures and status may change as filings and press coverage update.

Servier , an independent international pharmaceutical group governed by a foundation, and Day One Biopharmaceuticals , Inc. , a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that they have entered into a definitive agreement for Servier to acquire Day One for $21.50 per share in cash, representing a total equity value of approximately $2.5 billion